Dashboard
Manage Tickers

BMRNBIOMARIN PHARMACEUTICAL INC

Nasdaq biomarin.com


$ 86.21 $ -3.73 (-4.43 %)    

Monday, 05-Aug-2024 16:05:32 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 437.97 $ -13.38 (-2.98 %)
DIA $ 386.91 $ -10.32 (-2.6 %)
SPY $ 518.58 $ -15.52 (-2.91 %)
TLT $ 98.76 $ 0.52 (0.53 %)
GLD $ 222.59 $ -2.86 (-1.27 %)
$ 80.47
$ 80.45 x 100
-- x --
-- - --
$ 73.68 - $ 99.56
2,229,636
na
16.13B
$ 0.66
$ 62.88
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 04-26-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 04-28-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 10-28-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 04-29-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 10-29-2021 09-30-2021 10-Q
13 07-30-2021 06-30-2021 10-Q
14 04-30-2021 03-31-2021 10-Q
15 02-26-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-01-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 10-29-2019 09-30-2019 10-Q
21 08-02-2019 06-30-2019 10-Q
22 04-29-2019 03-31-2019 10-Q
23 02-28-2019 12-31-2018 10-K
24 10-26-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 04-27-2018 03-31-2018 10-Q
27 02-26-2018 12-31-2017 10-K
28 10-31-2017 09-30-2017 10-Q
29 08-02-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 02-27-2017 12-31-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-02-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-02-2015 09-30-2015 10-Q
37 08-05-2015 06-30-2015 10-Q
38 05-05-2015 03-31-2015 10-Q
39 03-02-2015 12-31-2014 10-K
40 10-28-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

biomarin-pharmaceutical-q2-2024-adj-eps-096-beats-035-estimate-sales-71203m-beat-66205m-estimate
Biomarin Pharmaceutical Q2 2024 Adj EPS $0...
08/05/2024 20:13:13

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate ...

biomarin-to-reduce-operating-expenses-to-achieve-roctavian-profitability-by-end-of-2025-focuses-commercial-operations-on-us-germany-and-italy-will-continue-monitoring-and-support-for-treated-patients
BioMarin To Reduce Operating Expenses To A...
08/05/2024 20:02:12

cantor-fitzgerald-reiterates-overweight-on-biomarin-pharmaceutical-maintains-110-price-target
Cantor Fitzgerald Reiterates Overweight on...
08/05/2024 13:49:58

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

canaccord-genuity-maintains-hold-on-biomarin-pharmaceutical-maintains-89-price-target
Canaccord Genuity Maintains Hold on Biomar...
07/25/2024 13:07:52

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and maintains $89 price t...

us-fda-approves-biomarins-brineura-for-children-under-3-years-with-cln2-disease
U.S. FDA Approves BioMarin's BRINEURA For ...
07/24/2024 20:25:39

Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show SymptomsSAN RAFAEL, Calif.,...

a-glimpse-into-the-expert-outlook-on-biomarin-pharmaceutical-through-10-analysts
A Glimpse Into The Expert Outlook On Bioma...
07/22/2024 17:00:44

cantor-fitzgerald-reiterates-overweight-on-biomarin-pharmaceutical-maintains-110-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/22/2024 15:22:34

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

100-invested-in-biomarin-pharmaceutical-20-years-ago-would-be-worth-this-much-today
$100 Invested In Biomarin Pharmaceutical 2...
07/18/2024 17:00:24

1000-invested-in-this-stock-20-years-ago-would-be-worth-16000-today
$1000 Invested In This Stock 20 Years Ago ...
07/16/2024 21:34:09

peering-into-biomarin-pharmaceuticals-recent-short-interest
Peering Into Biomarin Pharmaceutical's Rec...
07/04/2024 19:15:23

cracking-the-code-understanding-analyst-reviews-for-biomarin-pharmaceutical
Cracking The Code: Understanding Analyst R...
06/27/2024 16:01:35

wells-fargo-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-115
Wells Fargo Maintains Overweight on Biomar...
06/27/2024 15:20:16

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price targ...

biomarin-presents-data-highlighting-impact-of-voxzogo-in-bone-health-and-health-related-quality-of-life-in-achondroplasia-at-2024-iccbh
BioMarin Presents Data Highlighting Impact...
06/17/2024 12:34:20

New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of...

biomarin-presents-new-phase-3-4-year-data-underscoring-long-term-safety-and-efficacy-of-roctavian-at-international-society-on-thrombosis-and-haemostasis-2024-congress-in-bangkok-thailand-june-22-26-2024
BioMarin Presents New Phase 3, 4-Year Data...
06/07/2024 13:01:41

Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/04/2024 17:35:21

looking-into-biomarin-pharmaceuticals-recent-short-interest
Looking Into Biomarin Pharmaceutical's Rec...
05/28/2024 18:00:25

li-auto-was-one-of-the-worst-performing-stocks-last-week-are-these-10-large-cap-stocks-losers-in-your-portfolio-may-12-may-18-2024
Li Auto Was One Of The Worst-Performing St...
05/19/2024 23:17:26

Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw sign...

walmart-to-rally-over-17-here-are-10-top-analyst-forecasts-for-friday
Walmart To Rally Over 17%? Here Are 10 Top...
05/17/2024 11:41:28

baird-downgrades-biomarin-pharmaceutical-to-neutral-lowers-price-target-to-72
Baird Downgrades Biomarin Pharmaceutical t...
05/17/2024 09:20:19

Baird analyst Joel Beatty downgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Neutral and lowers the price t...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/15/2024 17:35:22

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION